ReviewFrontiers in oncology2026
Radiomics and artificial intelligence in precision radiotherapy for cervical cancer: a narrative review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) continues to impose a substantial global health burden and remains one of the most prevalent malignancies among women worldwide. Radiotherapy is a cornerstone treatment for locally advanced disease, and its precision critically impacts tumor control and treatment-related toxicity. Within the evolving paradigm of precision oncology, radiomics and artificial intelligence (AI) have emerged as promising tools to personalize radiotherapy by improving target delineation, predicting treatment response, refining prognostic stratification, and facilitating individualized toxicity risk assessment. This narrative review synthesizes and critically appraises the current evidence on the application of radiomics and AI in CC radiotherapy, focusing on three principal domains: automated target volume delineation, prediction of prognosis and treatment response, and forecasting of radiotherapy-induced toxicities. We further evaluate the methodological rigor and translational readiness of existing studies. Despite encouraging technical performance, most available evidence remains retrospective, with limited prospective validation and uncertain impact on clinical decision-making. Clinical implementation is further challenged by imaging heterogeneity, insufficient standardization, and limited model interpretability. Future research should prioritize large-scale multicenter validation, methodological standardization, and prospective evaluation to determine whether radiomics-guided strategies can meaningfully improve patient outcomes and support integration into routine clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.